TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.

Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, Allison ME, Alexander GJ, Piguet AC, Anty R, Anty R, Donaldson P, Aithal GP, Francque S, Van Gaal L, Clement K, Ratziu V, Dufour JF, Day CP, Daly AK, Anstee QM. · 2014

Read TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. by Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, Allison ME, Alexander GJ, Piguet AC, Anty R, Anty R, Donaldson P, Aithal GP, Francque S, Van Gaal L, Clement K, Ratziu V, Dufour JF, Day CP, Daly AK, Anstee QM. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4279183.txt.

Introduction

Yang-Lin Liu and a wide group of collaborators tested whether a common variant in the gene TM6SF2 speeds up liver scarring in fatty liver disease. Their study appeared in Nature Communications in 2014. The variant was already known to raise fat in the liver, but its link to lasting harm was unclear.

Patients with fatty liver disease were genotyped and their liver tissue was graded for fibrosis, the scarring that can lead to cirrhosis. Carriers of the variant showed more advanced scarring. The finding helps explain why fatty liver stays mild in some people and turns severe in others, and it adds a genetic marker that may help flag patients who need closer watch.

Catalog record

CREATORLiu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, Allison ME, Alexander GJ, Piguet AC, Anty R, Anty R, Donaldson P, Aithal GP, Francque S, Van Gaal L, Clement K, Ratziu V, Dufour JF, Day CP, Daly AK, Anstee QM.
YEAR2014
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4279183

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease By Yang-Lin Liu, Helen L Reeves, Alastair D Burt, Dina Tiniakos, Stuart McPherson, Julian B S Leathart, Michael E D Allison, Graeme J Alexander, Anne-Christine Piguet, Rodolphe Anty, Peter Donaldson, Guruprasad P Aithal Published in: Nature Communications DOI: 10.1038/ncomms5309 ABSTRACT Abstract Non-alcoholic fatty liver disease (NAFLD) is an increasingly common condition, strongly associated with the metabolic syndrome, that can lead to progressive hepatic fibrosis, cirrhosis and hepatic failure. Subtle inter-patient genetic variation and environmental factors combine to determine variation in disease progression. A common non-synonymous polymorphism in TM6SF2 (rs58542926 c.449 C>T, p.Glu167Lys) was recently associated with increased hepatic triglyceride content, but whether this variant promotes clinically relevant hepatic fibrosis is unknown. Here we confirm that TM6SF2 minor allele carriage is associated with NAFLD and is causally related to a previously reported chromosome 19 GWAS signal that was ascribed to the gene NCAN. Furthermore, using two histologically characterized cohorts encompassing steatosis, steatohepatitis, fibrosis and cirrhosis (combined n=1,074), we demonstrate a new association, independent of potential confounding factors (age, BMI, type 2 diabetes mellitus and PNPLA3 rs738409 genotype), with advanced hepatic fibrosis/cirrhosis. These findings establish new and important clinical relevance to TM6SF2 in NAFLD. Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of progressive liver disease characterized by increased hepatic triglyceride content (HTGC) in the absence of excess alcohol consumption1. NAFLD includes simple steatosis, non-alcoholic steatohepatitis, fibrosis and ultimately cirrhosis, and is strongly associated with features of the metabolic syndrome (obesity, insulin resistance/type 2 diabetes mellitus (T2DM) and dyslipidaemia)1. Reflecting the increasing prevalence of these conditions, NAFLD is estimated to affect approximately one-third of the population in many developed countries. Simple steatosis is generally considered to have a benign course and therefore to be of limited prognostic relevance2,3. However, some NAFLD patients exhibit progressive steatohepatitis leading to cirrhosis and/or hepatocellular carcinoma (HCC), conditions that confer increased morbidity and mortality1,4. Despite its high prevalence, only a minority of NAFLD patients progress to significant fibrosis and experience the associated morbidity1. Thus, similar to other common diseases (for example, obesity, T2DM and cardiovascular disease), NAFLD is best considered as a complex trait in which disease phenotype results from environmental exposures acting on a susceptible polygenic background that comprises multiple independent modifiers5,6,7. Genome-wide association studies (GWAS)8,9,10 and candidate-gene studies11,12,13,14,15 have contributed greatly to our understanding of the genetic contribution to NAFLD pathogenesis and variability of prognosis (reviewed in ref. 7). Among the loci identified, the non-synonymous single-nucleotide polymorphism (SNP) in PNPLA3 (rs738409 c.444 C>G, p.Ile148Met), patatin-like phospholipase domain containing 3, has been validated across multiple patient cohorts8,9,12,16. Importantly, carriage of this SNP has been robustly associated not only with steatosis but also with clinically relevant factors, including severity of hepatic fibrosis/cirrhosis and development of NAFLD-related HCC12,17,18. Recently, Kozlitina et al.19 showed that a non-synonymous SNP in TM6SF2 (rs58542926 c.449 C>T, p.Glu167Lys), transmembrane 6 superfamily member 2, a gene of unknown function on chromosome 19, was associated with proton magnetic resonance spectroscopy (1H-MRS) quantified HTGC based on genotyping with a genome-wide exome chip19. This variant has also been associated with dyslipidaemia and cardiovascular risk20. The TM6SF2 rs58542926 SNP lies within 50 kb of an NCAN gene variant (rs2228603 c.274 C>T, p.Pro92Ser) that has previously been associated with HTGC in another GWAS9,21. Both SNPs are in strong linkage disequilibrium (D′=0.926, r2=0.798). Conditioning on the TM6SF2 variant abrogated the effect of the NCAN variant while the reverse did not occur, suggesting that TM6SF2 rs58542926 is more strongly associated with the HTGC phenotype. Homozygote TM6SF2 rs58542926 minor (T) allele carriage was shown to be associated with a modest but statistically significant increase in 1H-MRS measured HTGC from 5.86±0.25% in CC homozygotes to 15.04±2.23% in TT homozygotes19. In vitro and in vivo functional studies also supported this conclusion but were unable to determine whether the effect of TM6SF2 was limited to steatosis or had broader clinical relevance, as has already been shown for PNPLA3 (ref. 19). The aim of the current study was, first, to determine whether the association with NAFLD reported by Kozlitina et al.19 could be independently validated; and, second, to establish whether the TM6SF2 rs58542926 variant was associated with clinically important disease end points that have prognostic relevance (in particular stage of hepatic fibrosis or development of NAFLD-related HCC). To address this, we perform a quantitative analysis within a well-characterized European Caucasian ‘discovery’ cohort with histologically characterized NAFLD, controlling for relevant co-morbidities and factors that have previously been linked with disease progression (age, gender, body mass index (BMI), presence of T2DM and PNPLA3 rs738409 genotype), and replicate our findings in a separate histologically characterized European Caucasian ‘validation’ cohort. To discover whether the TM6SF2 rs58542926 variant also confers an increased risk of NAFLD-related HCC, we perform a secondary case–control analysis comparing the overall ‘combined’ cohort of NAFLD patients to a cohort of NAFLD–HCC patients. RESULTS Increased TM6SF2 rs58542926 C>T minor allele carriage in NAFLD In the NAFLD discovery cohort, the TM6SF2 rs58542926 genotypes were confirmed to be in Hardy–Weinberg equilibrium with a minor allele frequency of 0.12, significantly higher than that observed in a reference Northern European population sample (MAF 0.07, http://browser.1000genomes.org) or a cohort of 265 Caucasian self-reported ‘healthy workers’ recruited from offices and factories locally in the North East of England (MAF 0.07) and so supportive of an association between these variants and NAFLD. Indeed, a gene-dosage effect was observed for both variants in the discovery cohort with the incidence of NAFLD increasing with the number of minor alleles possessed (X2 for trend, P=0.0008; Supplementary Table 1). A similar association was also confirmed for PNPLA3 rs738409, P=0.0001 (Supplementary Table 2). Specific histological components of the NAFLD disease phenotype were next assessed individually. TM6SF2 and degree of histological steatosis As a positive control, and consistent with our previously reported analysis12, carriage of the PNPLA3 rs738409 minor allele was significantly associated with degree of steatosis in multivariate analysis adopting an additive model adjusted for gender, age at biopsy, BMI and presence of T2DM (β=0.192±0.056, 95% confidence interval (CI) 0.082–0.301; P=6.74 × 10−4). However, in contrast to the report by Kozlitina et al.19, neither TM6SF2 rs58542926 (β=0.087±0.083, 95%CI −0.076 to 0.250; P=0.296) nor NCAN rs2228603 (β=0.050±0.085, 95%CI −0.116 to 0.216; P=0.554) were found to be significantly associated with degree of histologically determined steatosis in the 349-patient discovery cohort. This was also the case in the 725-patient validation cohort (P=0.17). However, a trend towards significance was observed when the two cohorts were combined (β=0.111±0.059, 95%CI −0.0041 to 0.2268; P=0.053), suggesting that an underlying effect on degree of steatosis may be present but of relatively small size. An effect became apparent when the multivariate analysis in the combined cohort was repeated after subdividing the cohort into those with mild steatosis (S0–1) and pronounced steatosis (S2–3). Here, carriage of each copy of the TM6SF2 rs58542926 C>T minor allele was associated with increased risk of greater steatosis (odds ratio (OR) 1.379, 95%CI 1.019–1.865; P=0.037), although with a marginal level of significance. TM6SF2 and severity of histological steatohepatitis Next, the association with steatohepatitis activity was tested using a composite score incorporating severity of necroinflammation and ballooning hepatocyte degeneration. TM6SF2 rs58542926, but not NCAN rs2228603, was associated with severity of steatohepatitis in the

Read the complete text